The Impact of Ineffective Esophageal Motility on Patients Undergoing Magnetic Sphincter Augmentation.

Autor:	Baison GN; Swedish Cancer Institute, Seattle, WA., Jackson AS; Swedish Cancer Institute, Seattle, WA., Wilshire CL; Swedish Cancer Institute, Seattle, WA., Bell RCW; Institute of Esophageal and Reflux Surgery, Englewood, CO., Lazzari V; University of Milano, IRCCS Policlinico San Donato, Milan, Italy., Bonavina L; University of Milano, IRCCS Policlinico San Donato, Milan, Italy., Ayazi S; Esophageal and Lung Institute, Canonsburg, PA., Jobe BA; Esophageal and Lung Institute, Canonsburg, PA., Schoppmann SF; Medical University of Vienna, Vienna, Austria., Dunn CP; University of Southern California, Los Angeles, CA., Lipham JC; University of Southern California, Los Angeles, CA., Dunst CM; The Oregon Cünic, Portland, OR., Farivar AS; Swedish Cancer Institute, Seattle, WA., Bograd AJ; Swedish Cancer Institute, Seattle, WA., Louie BE; Swedish Cancer Institute, Seattle, WA.
Jazyk:	angličtina
Zdroj:	Annals of surgery [Ann Surg] 2023 Apr 01; Vol. 277 (4), pp. e793-e800. Date of Electronic Publication: 2022 Jan 25.
DOI:	10.1097/SLA.0000000000005369
Abstrakt:	Objective: To evaluate and characterize outcomes of MSA in patients with IEM. Summary Background Data: MSA improves patients with gastroesophageal reflux and normal motility. However, many patients have IEM, which could impact the outcomes of MSA and discourage use. Methods: An international, multi-institutional case control study of IEM patients undergoing MSA matched to normal patients was performed. Primary outcomes were new onset dysphagia and need for postoperative interventions. Results: A total of 105 IEM patients underwent MSA with matching controls. At 1 year after MSA: GERD-Health Related Quality of Life was similar; DeMeester scores in IEM patients improved to 15.7 and 8.5 in controls ( P = 0.021); and normalization of the DeMeester score for IEM = 61.7% and controls = 73.1% ( P = 0.079).In IEM patients, 10/12 (83%) with preop dysphagia had resolution; 11/66 (17%) had new onset dysphagia and 55/66 (83%) never had dysphagia. Comparatively, in non-IEM patients, 22/24 (92%) had dysphagia resolve; 2/24 (8%) had persistent dysphagia; 7/69 (10%) had new onset dysphagia, and 62/69 (90%) never had dysphagia.Overall, 19 (18%) IEM patients were dilated after MSA, whereas 12 (11%) non-IEM patients underwent dilation ( P = 0.151). Nine (9%) patients in both groups had their device explanted. Conclusions: Patients with IEM undergoing MSA demonstrate improved quality of life and reduction in acid exposure. Key differences in IEM patients include lower rates of objective GERD resolution, lower resolution of existing dysphagia, higher rates of new onset dysphagia and need for dilation. GERD patients with IEM should be counselled about these possibilities. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu